Deutsche Bank Lowers Kenvue (KVUE) PT to $18, Keeps a Hold Rating

Kenvue Inc. (NYSE:KVUE) is one of the most buzzing stocks to buy with huge upside potential. On October 24, Deutsche Bank lowered the firm’s price target on Kenvue to $18 from $20 and kept a Hold rating on the shares.

Earlier on October 10, JPMorgan also lowered the firm’s price target on Kenvue to $21 from $24 and kept an Overweight rating on the shares as part of a Q3 2025 preview for the household, personal care, and beauty group.

JPMorgan anticipates that most large-cap companies in this group will likely report another weak quarter. This is attributed to the ‘still depressed’ consumer demand in the US and decelerating trends in Western Europe. The difficult market backdrop is further worsened by retailers reducing their inventory levels.

Kenvue Inc. (NYSE:KVUE) operates as a consumer health company in the US, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health & Beauty, and Essential Health.

While we acknowledge the potential of KVUE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.